A dicalcium 2,3,5,6-tetrahydroxy-4-[[3,4,5-trihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]hexanoate dibromide written confirmation (dicalcium 2,3,5,6-tetrahydroxy-4-[[3,4,5-trihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]hexanoate dibromide WC) is an official document issued by a regulatory agency to a dicalcium 2,3,5,6-tetrahydroxy-4-[[3,4,5-trihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]hexanoate dibromide manufacturer, verifying that the manufacturing facility of a dicalcium 2,3,5,6-tetrahydroxy-4-[[3,4,5-trihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]hexanoate dibromide active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting dicalcium 2,3,5,6-tetrahydroxy-4-[[3,4,5-trihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]hexanoate dibromide APIs or dicalcium 2,3,5,6-tetrahydroxy-4-[[3,4,5-trihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]hexanoate dibromide finished pharmaceutical products to another nation, regulatory agencies frequently require a dicalcium 2,3,5,6-tetrahydroxy-4-[[3,4,5-trihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]hexanoate dibromide WC (written confirmation) as part of the regulatory process.
click here to find a list of dicalcium 2,3,5,6-tetrahydroxy-4-[[3,4,5-trihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]hexanoate dibromide suppliers with Written Confirmation (WC) on PharmaCompass.